ADHD

A meta-analysis found methylphenidate treatment of children with ADHD improves academic productivity more than accuracy, effecting performance in math more than reading.

Treating adults with ADHD challenges clinicians to overcome associated stigma, complexity and controversy to help patients overcome this hidden disability.

This is the first national study to analyze prescription rates of ADHD, anxiety disorders and depression psychiatric medications in youth.

The percentage of women who filled at least 1 prescription rose 344% from 2003 to 2015.

Researchers compared incoming freshman students’ medication intake to upperclassmen, finding that of both groups, only 53% took their medication.

Medicaid prior authorization policies could influence whether ADHD treatments follow or diverge from best practices.

Participants displayed statistically significant reductions in ADHD symptoms, improvements in executive functioning, and declines in anxiety symptoms.

Approximately 44.7% of the patients with FMS screened positive for adult ADHD.

More children with ADHD in US receive medication and school support than recommended psychosocial treatments.

A new model-based approach could improve the extended release methylphenidate form to better function in treating ADHD.

Patients with ADHD have an increased risk of developing STIs later in life compared with the non-ADHD comparisons.

Improvement in early screening, the development of biomarkers and therapy testing will change the screening process for autism and ADHD.

More parents of children with ADHD report seeking information about the condition from online sources than from the healthcare provider.

The study suggests those with different types of ADHD have impairments in unique brain systems.

Risks increase when a child’s mother, versus their father has a history of homelessness.

The first-of-its-kind prescription digital medicine video game plans for regulatory filing in the first half of 2018.

Evening-dosed psychostimulant is the first long-acting MPH single-dose formulation to show improvements in at-home early morning functional impairment.

The drug is being tested for the first time on a large scale adult patient population.

In response to patient concerns about dosing options and duration of effect, researchers at Shire Pharmaceuticals created Mydayis for the treatment of ADHD symptoms.

The treatment is a once-daily, extended-release liquid medication, but does not require refrigeration or pharmacy reconstitution.

A father's age can negatively affect the social development of his child.

Diets high in sugar and saturated fat are associated with ADHD.

Report: consistent stimulant use into adulthood produced an inch of deviation.

UK study finds misdiagnosis in some ADHD.

Researchers compared the safety and efficacy of leading ADHD treatments.